Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638088 | 0.90 | TGFBR1 (0.40) | TGFBR1KDRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21363867 | 0.90 | KMO (0.39) | TGFBR1KDRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15640064 | 0.87 | SLC6A2 (0.45) | TGFBR1KDRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21363871 | 0.86 | EGLN2 (0.43) | TGFBR1KDREGLN2 | |
| SCHEMBL21363868 | 0.85 | EGLN2 (0.39) | TGFBR1KDRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15640070 | 0.84 | TGFBR1 (0.42) | TGFBR1KDREGFREGLN2KMO | |
| SCHEMBL15638028 | 0.81 | TGFBR1 (0.54) | TGFBR1KDRKMOCYP11B2 | |
| SCHEMBL15637970 | 0.80 | PDE4A (0.38) | TGFBR1KDRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15639358 | 0.80 | KDR (0.47) | TGFBR1KDRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21363872 | 0.79 | SLC6A2 (0.38) | TGFBR1KDRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | TGFBR1 3/4885KDR 147/4885SLC6A2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.